P

Penn State Health Milton S. Hershey Medical Center | Neuro-Oncology Department

Research site
(Unclaimed)
Location
500 University Drive, Hershey, Pennsylvania, United States of America
Site insights

Top conditions

Heart Failure (6 trials)

Cardiomyopathies (5 trials)

Endometriosis (3 trials)

Nevus (2 trials)

Pelvic Pain (2 trials)

Top treatments

CC-93538
Temozolomide
Patidegib
Gemcitabine
STAR-0215
Cannabidiol
Reldesemtiv
Mavacamten
Cilofexor
Bexotegrast

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

24 of 71
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in s...

Enrolling
Sickle Cell Disease
Other: Mitapivat-matching placebo
Drug: Mitapivat

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Enrolling
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

The purpose of this study is to determine the effect of ixazomib citrate maintenance therapy on progression-free survival (PFS), compared to placebo,...

Active, not recruiting
Autologous Stem Cell Transplant
Multiple Myeloma
Drug: Ixazomib Citrate
Drug: Placebo

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1...

Enrolling
Hereditary Angioedema
Drug: STAR-0215

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Sub...

Active, not recruiting
Inclusion Body Myositis
Drug: ABC008

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evalu...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538
Other: Placebo

A prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System, with 2:1 study vs. active concurrent control group allocati...

Active, not recruiting
Ventricular Dysfunction, Left
Device: Revivent TC

This is a non-randomized, prospective, multi-center Early Feasibility Study to evaluate the AccuCinch® Ventricular Restoration System in Patients wit...

Active, not recruiting
Cardiomyopathy, Dilated
Heart Failure
Device: AccuCinch® Ventricular Restoration

This is a non-randomized, prospective, multi-center Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients with Prior M...

Active, not recruiting
Cardiomyopathy, Dilated
Heart Failure
Device: AccuCinch® Ventricular Restoration System

The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Ther...

Active, not recruiting
Arrhythmia, Ventricular
Tachycardia, Ventricular
Device: mCRM Therapy System

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Enrolling
Heart Failure
Device: Investigational LUX-Dx ICM Implant

This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A...

Active, not recruiting
Cystic Fibrosis
Chronic Pseudomonas Aeruginosa Infection
Drug: BX004-A
Drug: Placebo

This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed...

Enrolling
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Non-Hodgkin Lymphoma
Drug: NKTR-255 at 3.0 μg/kg
Drug: NKTR-255 at 3.0/6.0 μg/kg

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with adva...

Enrolling
Metastatic Cancer
Advanced Cancer
Drug: MRTX849
Drug: Afatinib

To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids administered every 2 weeks in ambulato...

Active, not recruiting
Duchenne Muscular Dystrophy
Drug: Corticosteroids
Drug: Placebo

This prospective, global, multicenter, single arm post-approval study is designed to investigate the clinical use and safety of the Lutonix® 035 AV D...

Enrolling
Arteriovenous Fistula
Device: LUTONIX 035 Drug Coated Balloon PTA Catheter

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment o...

Enrolling
Idiopathic Pulmonary Fibrosis
Drug: PLN-74809
Drug: Placebo

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Enrolling
Eosinophilic Esophagitis
Drug: CC-93538

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only
Acute Myocardial Infarction
Combination Product: Placebo
Combination Product: Selatogrel
Locations recently updated

Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema

Enrolling
Emphysema
Alpha 1-Antitrypsin Deficiency
Drug: INBRX-101
Drug: Zemaira

Trial sponsors

Penn State Health logo

Penn State Health (13 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems